Guardant Health price target raised to $60 from $55 at Barclays

Barclays raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps an Overweight rating on the shares. The firm says the company’s ignition business is inflecting, and the guidance raise on Shield and Oncology give it confidence “that things are just getting started.” Barclays believes the stock can “continue its run.”